lorlatinib


( Last Updated : September 13, 2021)
Generic Name:
lorlatinib
Project Status:
Active
Therapeutic Area:
ALK-positive locally advanced or metastatic non-small cell lung
Manufacturer:
Pfizer Canada
Brand Name:
Lorbrena
Project Line:
Reimbursement Review
Project Number:
PC0249-000
Tumour Type:
Lung
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC)
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open20-May-21
Call for patient/clinician input closed12-Jul-21
Clarification:

- Patient input submission received from Lung Cancer Canada and CanCertainty

Submission received18-Jun-21
Submission accepted07-Jul-21
Review initiated08-Jul-21
Draft CADTH review report(s) provided to sponsor for comment24-Sep-21
Deadline for sponsors comments05-Oct-21
CADTH review report(s) and responses to comments provided to sponsor29-Oct-21
Expert committee meeting (initial)10-Nov-21